VRTXVertex Pharmaceuticals
Is it safe?
Solid, nothing alarming. Safe balance sheet, some accounting flags, quality moderate.
Financially healthy, low distress risk Altman Z-score, a bankruptcy-risk model from five balance-sheet ratios.
Some accounting flags, worth a closer look Beneish M-score, a forensic model that detects earnings-manipulation patterns (receivables outrunning sales, margins slipping, accrual-heavy profit).
Mixed fundamental signals Piotroski F-score, nine pass/fail tests of year-over-year financial health across profitability, balance sheet and efficiency. 7 to 9 is strong, 0 to 3 weak.
Moderate price swings, typical volatility. Worst drawdown -42% · now 9% below its 52-week high.
Unless marked, from SEC EDGAR, as of Dec 31, 2025.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can VRTX take a bad year?
The deepest fall in VRTX's price history on file is −42%; it is 8.6% below its high today.
Altman Z-score · distress below 1.8 · safe above 3 · safe zone, the balance sheet is not what threatens this one
- Annualised volatility
- 32%
Annualised volatility · about as steady as the market itself
- Worst drawdown on file
- −42%
Worst drawdown on file · −8.6% today
Details›
- Cash and short-term investments
- $7.85B
- EBITDA, trailing twelve months
- $5.00B
- Operating profit, trailing twelve months
- $4.78B
- Annualised volatilitytwo years of daily moves
- 32%
- Worst drawdown on file
- −42%
- Below its 52-week high
- 8.6%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Biotechnology
The closest names by size in the same industry